• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters
Displaying 39-53 of 106 results

1034 Exhibit: Ex 1034 Plaintiffs’ Initial Infringement Contentions to Def Sandoz Inc

Document IPR2023-00478, No. 1034 Exhibit - Ex 1034 Plaintiffs’ Initial Infringement Contentions to Def Sandoz Inc (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1041 Exhibit: Ex 1041 LYNPARZA™ olaparib Prescribing Information

Document IPR2023-00478, No. 1041 Exhibit - Ex 1041 LYNPARZA™ olaparib Prescribing Information (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1002 Exhibit: Ex 1002 Declaration Of John P Fruehauf, MD, PhD

Document IPR2023-00478, No. 1002 Exhibit - Ex 1002 Declaration Of John P Fruehauf, MD, PhD (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1010 Exhibit: Ex 1010 John C Byrd, et al

Document IPR2023-00478, No. 1010 Exhibit - Ex 1010 John C Byrd, et al (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1035 Exhibit: Ex 1035 CALQUENCE® acalabrutinib Prescribing Information

Document IPR2023-00478, No. 1035 Exhibit - Ex 1035 CALQUENCE® acalabrutinib Prescribing Information (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1029 Exhibit: Ex 1029 Erica K Evans, et al

Document IPR2023-00478, No. 1029 Exhibit - Ex 1029 Erica K Evans, et al (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1040 Exhibit: Ex 1040 JAKAFI™ ruxolitinib Prescribing Information

Document IPR2023-00478, No. 1040 Exhibit - Ex 1040 JAKAFI™ ruxolitinib Prescribing Information (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1005 Exhibit: Ex 1005 US Patent No 9,758,524 to Barf, et al

Document IPR2023-00478, No. 1005 Exhibit - Ex 1005 US Patent No 9,758,524 to Barf, et al (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1023 Exhibit: Ex 1023 Prosecution History of US Patent No 9,758,524 Part 2

Document IPR2023-00478, No. 1023-2 Exhibit - Ex 1023 Prosecution History of US Patent No 9,758,524 Part 2 (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1043 Exhibit: Ex 1043 Yan Bao, et al

Document IPR2023-00478, No. 1043 Exhibit - Ex 1043 Yan Bao, et al (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1023 Exhibit: Ex 1023 Prosecution History of US Patent No 9,758,524 Part 3

Document IPR2023-00478, No. 1023-3 Exhibit - Ex 1023 Prosecution History of US Patent No 9,758,524 Part 3 (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1022 Exhibit: Ex 1022 Simon Rule, et al,

Document IPR2023-00478, No. 1022 Exhibit - Ex 1022 Simon Rule, et al, (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1027 Exhibit: Ex 1027 US Food and Drug Administration, Guidance for Industry

Document IPR2023-00478, No. 1027 Exhibit - Ex 1027 US Food and Drug Administration, Guidance for Industry (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1004 Exhibit: Ex 1004 Prosecution History of US Patent No 10,272,083 Part 2

Document IPR2023-00478, No. 1004-2 Exhibit - Ex 1004 Prosecution History of US Patent No 10,272,083 Part 2 (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze

1016 Exhibit: Ex 1016 IMBRUVICA™ ibrutinib Prescribing Information

Document IPR2023-00478, No. 1016 Exhibit - Ex 1016 IMBRUVICA™ ibrutinib Prescribing Information (P.T.A.B. Feb. 3, 2023)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 8 >>